Cardiotonic bipyridine amrinone slows myosin-induced actin filament sliding at saturating [MgATP]
Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift
Previously reported effects of amrinone on skeletal muscle function suggest that the drug reduces the rate constant of myosin cross-bridge dissociation. We have used the in vitro motility assay to further elucidate the mechanism underlying this effect and to aid these studies a new, improved,. lament tracking software was developed in the Matlab(TM) environment. The experiments were carried out at 30degreesC using heavy meromyosin from fast rabbit muscle and rhodamine-phalloidin labeled actin. laments. A slowing effect of amrinone on. lament sliding velocity at 1 mM MgATP was observed at drug concentrations >0.3 mM. This effect showed signs of saturation at the highest drug concentrations (1-2 mM) that could be readily tested. The sliding velocity exhibited hyperbolic dependence on [ MgATP] with a V-max of 7.2 +/- 0.9 mum/s and a K-M of 0.18 +/- 0.02 mM. Amrinone (1 mM) reduced V-max by 32 +/- 5% (P < 0.01) and K-M by 42 &PLUSMN; 8% (P < 0.05; n = 4). These results are accounted for in the most straightforward way by a model where amrinone acts directly on the actomyosin system and reduces the rate constant of MgADP release. Such a well-defined effect on the myosin cross-bridge cycle makes the drug a potentially useful pharmacological tool for further studies of myosin function both in vitro and in the ordered. lament array of a living muscle fiber.
|Enheter & grupper|
Ämnesklassifikation (UKÄ) – OBLIGATORISK
|Tidskrift||Journal of Muscle Research and Cell Motility|
|Status||Published - 2003|
|Peer review utförd||Ja|